Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Mediator kinase inhibitors suppress triple-negative breast cancer growth and extend tumor suppression by mTOR and AKT inhibitors

Proceedings of the National Academy of Sciences(2024)10.1073/pnas.2414501121Source: DataRank Database

Mediator kinase inhibitors suppress triple-negative breast cancer growth and extend tumor suppression by mTOR and AKT inhibitors is a research paper published in Proceedings of the National Academy of Sciences (2024). On theSindex it has a DataRank of 0.330. It has been cited 8 times.

N/A

0.330DataRank · unranked

Scored on demand from live citation data

Open Access8 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)Impact (FWCI 2.24)OA: hybridTopics (59)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.330

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (14)

Jiaxin Liang ORCID,Amanda C. Sharko,Thomas A. Hilimire ORCID,Jing Li ORCID,Jürgen Loskutov

Live enrichment

PubMed:39541354 PMC:PMC11588072 OpenAlex:https://openalex.org/W4404371503

HHS | NIH

Grant: P20GM109091

HHS | NIH

Grant: R43CA271996

HHS | NIH

Grant: R01CA266027

HHS | NIH

Grant: R44CA203184

HHS | NIH

Grant: P20GM121322

HHS | NIH

Grant: CA148671

HHS | NIH

Grant: CA223622

HHS | NIH

Grant: U54GM104942

NCI NIH HHS

Grant: R03 CA223622

NCI NIH HHS

Grant: R01 CA148671

FWCI

2.24

Citation Percentile

0.9%

Citation Trend

2025

2026

hybridLicense: cc-by

journalhttps://www.pnas.org/doi/pdf/10.1073/pnas.2414501121

publisherhttps://www.pnas.org/doi/pdf/10.1073/pnas.2414501121

publisherhttps://pnas.org/doi/pdf/10.1073/pnas.2414501121

journalhttps://doi.org/10.1073/pnas.2414501121

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39541354

Fields of Study

Advanced Breast Cancer TherapiesPI3K/AKT/mTOR signaling in cancerCancer Mechanisms and TherapyTriple Negative Breast NeoplasmsHumansAnimalsProto-Oncogene Proteins c-aktFemaleMiceTOR Serine-Threonine KinasesProtein Kinase InhibitorsCell Line, TumorCyclin-Dependent Kinase 8Xenograft Model Antitumor AssaysMTOR InhibitorsPyrimidinesCyclin-Dependent KinasesCell ProliferationSignal TransductionPyrroles

MeSH Terms

MTOR InhibitorsAnimalsFemaleHumansPyrimidinesPyrrolesSignal TransductionCyclin-Dependent KinasesXenograft Model Antitumor AssaysCell Line, TumorProtein Kinase InhibitorsCell ProliferationProto-Oncogene Proteins c-aktMiceCyclin-Dependent Kinase 8TOR Serine-Threonine KinasesTriple Negative Breast Neoplasms

Keywords

PI3K/AKT/mTOR pathwayCancer researchProtein kinase BEverolimusmTORC1In vivoTriple-negative breast cancerBreast cancerKinaseMedicineBiologyCancerPharmacologySignal transductionOncologyInternal medicineCell biologyMetastasisMtorTriple Negative Breast CancerCdk8Mediator Kinase

Sustainable Development Goals

SDG 0: Good health and well-being